Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 340.4 DKK | +3.09% | +6.31% | +69.02% | |
| Dec. 04 | Roche enters obesity drugs race with $2.7 bln Carmot deal | RE |
| Dec. 04 | Roche enters obesity drugs race with $2.7 bln Carmot deal | RE |
| Sales 2023 * | 391M 56.81M | Sales 2024 * | 1.19B 172M | Capitalization | 19.85B 2.89B |
|---|---|---|---|---|---|
| Net income 2023 * | -494M -71.8M | Net income 2024 * | - 0 | EV / Sales 2023 * | 45,8x |
| Net cash position 2023 * | 1.93B 281M | Net cash position 2024 * | 2.8B 407M | EV / Sales 2024 * | 14,4x |
| P/E ratio 2023 * | -28,9x | P/E ratio 2024 * | -168x | Employees | 249 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.19% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +3.09% | ||
| 1 week | +7.93% | ||
| Current month | +1.31% | ||
| 1 month | +11.61% | ||
| 3 months | +31.84% | ||
| 6 months | +33.70% | ||
| Current year | +69.02% |
1 week
316.60
347.80
1 month
274.40347.80
Current year
198.00347.80
1 year
189.30347.80
3 years
69.55347.80
5 years
69.55347.80
10 years
57.50347.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 2009 | |
| Director of Finance/CFO | - | Oct. 31 | |
Danilo Verge
CTO | Chief Tech/Sci/R&D Officer | - | 2020 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 65 | 2019 |
| Chairman | 68 | 2014 | |
Kirsten Drejer
BRD | Director/Board Member | 67 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.04% | 4 M€ | -8.24% | ||
| 2.01% | 67 M€ | +5.27% | - | |
| 0.67% | 33 M€ | -5.74% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-04 | 340.4 | +3.09% | 345,491 |
| 23-12-01 | 330.2 | -1.73% | 315,124 |
| 23-11-30 | 336 | +2.63% | 395,391 |
| 23-11-29 | 327.4 | +1.99% | 158,350 |
| 23-11-28 | 321 | +0.25% | 354,063 |
Delayed Quote Nasdaq Copenhagen, December 04, 2023 at 10:59 am EST
More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
08:30am
- R&D Day
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
340.4DKK
Average target price
365.33DKK
Spread / Average Target
+7.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +69.02% | 2 807 M $ | |
| +21.42% | 90 488 M $ | |
| +14.11% | 86 658 M $ | |
| -4.62% | 34 551 M $ | |
| +20.96% | 26 777 M $ | |
| -33.49% | 23 629 M $ | |
| -25.33% | 20 547 M $ | |
| -17.63% | 19 529 M $ | |
| -2.44% | 11 507 M $ | |
| +25.50% | 10 906 M $ |
